Refine
Year of publication
Language
- English (31)
Has Fulltext
- yes (31)
Is part of the Bibliography
- no (31)
Keywords
- Multiple sclerosis (2)
- Neuroinflammation (2)
- ceramides (2)
- inflammation (2)
- macrophage (2)
- pain (2)
- sphingolipids (2)
- sphingosine kinase (2)
- stroke (2)
- A498 cells (1)
- AMP-activated kinase (1)
- Acquired resistance (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Autoimmune encephalomyelitis (1)
- Biomarkers (1)
- Brain injury (1)
- CNDAC (1)
- CTGF (1)
- CYP1A1 (1)
- Cancer (1)
- DCK (1)
- DNA damage (1)
- Diagnostic markers (1)
- Entorhinal cortex lesion (1)
- FTY720 (1)
- G-protein-coupled receptors (1)
- G2A (1)
- GEMs (1)
- GPCR (1)
- Glycolysis (1)
- Gαq/11 (1)
- HCC marker (1)
- HIV (1)
- HIV-1 (1)
- IFN-β (1)
- Intrinsic resistance (1)
- Leukemia (1)
- Lipid signaling (1)
- Lpar2 (1)
- Lysophosphatidic acids (1)
- MLV (1)
- MRP4 (1)
- Mitochondrial ROS (1)
- Nociception (1)
- Oncology (1)
- Oxidative phosphorylation (1)
- PKA (1)
- PRG-1 (1)
- RCC (1)
- S1P receptors (1)
- SAMHD1 (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- Sapacitabine (1)
- Spinal cord (1)
- Structural plasticity (1)
- T-cell homing (1)
- acute inflammation (1)
- adenosine receptors (1)
- analgesia (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- beta blockade (1)
- bioactive lipids (1)
- bioactive phospholipids (1)
- biomarker (1)
- blood pressure (1)
- breast cancer (1)
- cAMP (1)
- caloric restriction (1)
- cannabinoid receptor type 1 (1)
- cortical network (1)
- data science (1)
- dendritic cells (1)
- eNPP2 (1)
- endocannabinoids (1)
- epigenetics (1)
- exercise (1)
- fibrosarcoma (1)
- glucose metabolism (1)
- graft rejection (1)
- hepatitis C (1)
- histone deacetylase (1)
- human pain models (1)
- human pharmacology (1)
- hyperglycemia (1)
- ischemic type biliary lesions (1)
- mast cells (1)
- microlesions (1)
- migration (1)
- multiple sclerosis (1)
- orthopic liver transplantation (1)
- perineurium (1)
- polarization (1)
- post-exercise hypotension (1)
- prostaglandin E (1)
- prostaglandins (1)
- psychiatric disorders (1)
- regulatory T helper cells (1)
- resolution (1)
- sciatic nerve (1)
- smooth muscle cells (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine 1-phosphate homologues (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine-1-phosphate (1)
- synapse (1)
- toll-like receptor (1)
- tumor pain (1)
- vascular biology (1)
- xenobiotics (1)
- fingolimod (1)
Institute
- Medizin (29)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (6)
- Biochemie, Chemie und Pharmazie (2)
- Biowissenschaften (2)
- Pharmazie (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
- Institut für Ökologie, Evolution und Diversität (1)
- Interdisziplinäres Zentrum für Neurowissenschaften Frankfurt (IZNF) (1)
- Senckenbergische Naturforschende Gesellschaft (1)
Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate, functions as activator and substrate of the triphosphohydrolase SAMHD1 and is subject to SAMHD1-mediated inactivation. Retrospective immunohistochemical analysis of bone marrow specimens from AML patients at diagnosis revealed that SAMHD1 expression in leukemic cells inversely correlates with clinical response to decitabine, but not to azacytidine. SAMHD1 ablation increases the antileukemic activity of decitabine in AML cell lines, primary leukemic blasts, and xenograft models. AML cells acquire resistance to decitabine partly by SAMHD1 up-regulation. Together, our data suggest that SAMHD1 is a biomarker for the stratified use of hypomethylating agents in AML patients and a potential target for the treatment of decitabine-resistant leukemia.